Release Date: 2024-06-12

Immunotherapy in Brain, Head and Neck Cancer

Nuriye Ozdemir (Author), Imdat Eroglu (Author), Ozan Yazici (Author)

Release Date: 2024-06-12

Besides immunotherapy, several other pathways are targeted in Head and Neck (HNC) for future treatment. HRAS, NTRK, MSI, NOTCH, and PIK3A are targetable pathways for HNC. Tipifarnib showed promising results in patients with HNC having HRAS mutation in phase 2 studies. Xevinapant, a potent oral inhibitor of the apoptosis proteins antagonist, is another novel molecule [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inImmunotherapy in Human Cancers
    First Page151
    Last Page166
    DOIhttps://doi.org/10.69860/nobel.9786053359388.11
    Page Count16
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Besides immunotherapy, several other pathways are targeted in Head and Neck (HNC) for future treatment. HRAS, NTRK, MSI, NOTCH, and PIK3A are targetable pathways for HNC. Tipifarnib showed promising results in patients with HNC having HRAS mutation in phase 2 studies. Xevinapant, a potent oral inhibitor of the apoptosis proteins antagonist, is another novel molecule tested as a treatment option in HNC. A phase 2 trial showed that the addition of xevinapant to the CRT in locally advanced HNC results in very promising 5-yr OS benefits (53 % vs 28 %) compared to the CRT+placebo ( Multiomic studies (especially genomic and transcriptomic) are going on. Using multi-omics for the guidance of treatment could increase the PFS of the patients.
    Pembrolizumab is recommended alone or in combination with cisplatin /carboplatin and 5-FU chemotherapy, especially in tumors with PD-L1 CPS ≥ 1 for metastatic/unresectable disease in the first-line treatment. Single-agent pembrolizumab is an acceptable treatment choice especially in patients with CPS ≥ 20. Nivolumab and pembrolizumab are also recommended in subsequent lines if disease progression occurs after the first platinum-based treatment. For locally advanced HNC, studies on nivolumab and pembrolizumab with radiation therapy or CRT are mainly based on safety data and are immature. Although KEYNOTE-412 failed to show event-free survival and OS benefit when combined with CRT, patients with high PD-L1 expression may improve clinically. Although neoadjuvant immunotherapy showed promising results in phase 2 studies, further phase 3 studies are required to use it as a standard treatment option. HNCs are a heterogeneous group of cancers with different etiological, anatomical, and tumor microenvironmental features. Combining the different immunotherapies and chemotherapy with immunotherapy could be an acceptable option to overcome these barriers. Besides immunotherapy, several novel pathways are under investigation for targeted therapies in patients with HNC.

    Ozan Yazici (Author)
    MD, Professor of Internal Medicine, Gazi University
    https://orcid.org/0000-0003-0038-3569
    3Medical Student Faculty of Medicine Hacettepe University 2006 Research Assistant İç Hastalıkları Anabilim Dalı/İç Hastalıkları Ankara University Faculty of Medicine 2011 M.D.Subspecialist Education Medical Oncology Ankara Numune Education and Research Hospital 2014 Assoc. Prof. Medical Oncology Gazi University 2018-2022 Proföser Tıbbi Onkoloji Bilim Dalı Gazi University 2022-

    Imdat Eroglu (Author)
    MD, Assistant Professor, Gazi University
    https://orcid.org/0000-0001-6619-4141
    3IMDAT EROĞLU Gazi University Faculty of Medicine, Department of Medical Oncology,Research/Clinical Fellowship (2023-…) Hacettepe University Faculty of Medicine, Department Internal Medicine, Research Assistant (2018-2023 ) Gazi University Faculty of Medicine (2010 – 2017) Current: Oncology trainee: Gazi University Facult of Medicine/Turkey Oct 2023 Internal Medicine Specialist: Muradiye State Hospital/Turkey Feb 2023- Oct 2023 Internal Medicine Research Assistant: Hacettepe University /Turkey May 2018-Feb 2023 Observership: Medical University of Warsaw, Transplantation Surgery/Poland Aug 2014 Hacettepe University Faculty of Medicine, Turkey 2022

    Nuriye Ozdemir (Author)
    MD, Professor of Internal Medicine, Gazi University
    https://orcid.org/0000-0002-9235-9592
    3Nuriye Özdemir Academical tittle Prof. Dr. Affillation Gazi Üniversitesi Tıp Fakültesi A. EDUCATION Year Speciality Affillation Degree 2018 Medical Oncology Ankara Yıldırım Beyazıt University Assoc. Prof. Dr. 2011 Medical Oncology Ankara Numune Education and Research Hospital M.D. (Specialist) 2007 Medical Oncology Ankara Yıldırım Beyazıt University M.D. (Specialist) 2002 Medical Oncology Ankara Numune Education and Research Hospital Research Asistant 1996 Tıp Fakültesi Ankara University Faculty of Medicine M.D.

    • Ansell SM. Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management. Am J Hematol. 2020 Aug 1;95(8):978–89.

    • Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, et al. Hodgkin lymphoma. Nature Reviews Disease Primers 2020 6:1. 2020 Jul 23;6(1):1–25.

    • Vassilakopoulos TP, Chatzidimitriou C, Asimakopoulos J V., Arapaki M, Tzoras E, Angelopoulou MK, et al. Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. Cancers (Basel). 2019 Aug 1;11(8).

    • Marei HE, Hasan A, Pozzoli G, Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 2023 Dec 1;23(1).

    • Iranzo P, Callejo A, Assaf JD, Molina G, Lopez DE, Garcia-Illescas D, et al. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front Med (Lausanne). 2022 May 30;9:875974.

    • Meng L, Wu H, Wu J, Ding P, He J, Sang M, et al. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis. 2024 Jan 1;15(1).

    • Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. N Engl J Med. 2015 Jan 1;372(4):311.

    • Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study. Lancet Oncol. 2016 Sep 1;17(9):1283.

    • Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. JOURNAL OF CLINICAL ONCOLOGY Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36:1428–39.

    • Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, et al. Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022 Jun 6;139(25):3605.

    • Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman TA, Lee HJ, et al. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. Journal of Clinical Oncology. 2019 Aug 8;37(23):1997.

    • Bröckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth T V., et al. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol. 2020 Jun 1;6(6):1.

    • Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. Journal of Clinical Oncology. 2016 Nov 11;34(31):3733.

    • Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood [Internet]. 2019 Oct 10 ;134(14):1144.

    • Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023 Sep 9;142(10):878.

    • Armand P, Chen Y Bin, Redd RA, Joyce RM, Bsat J, Jeter E, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 Jul 7;134(1):22.

    • Yu W, Geng M, Hao J, Yan Z, Mi JQ. Real-World Experience of PD-1 Inhibitors for Relapsed and Refractory Hodgkin Lymphoma: A Multicenter Retrospective Analysis of Patients in China. Acta Haematol. 2023 Aug 10;146(4):310–8.

    • Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y, et al. A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. Clinical Cancer Research. 2019 Dec 15;25(24):7363–9.

    • Song Y, Zhou K, Jin C, Qian Z, Hou M, Fan L, et al. Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). Front Oncol. 2022 Jul 7;12.

    • Lin N, Zhang M, Bai H, Liu H, Cui J, Ke X, et al. Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. Eur J Cancer. 2022 Mar 1;164:117–26.

    • Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, et al. Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lympho-ma: Phase 1 Results of a Multicenter Phase 1/2 Clinical Trial. Lancet Haematol. 2020 Sep 1;7(9):e660.

    • Lin AY, Schnitter JM, Gordon LI. Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma. Immunotargets Ther. 2022;11:1.

    • Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduction and Targeted Therapy 2022 7:1. 2022 Sep 19;7(1):1–27.

    • Tobin JWD, Bednarska K, Campbell A, Keane C. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. Cells. 2021;10(5).

    • Herrera AF, Lavie D, Johnson NA, Avigdor A, Borchmann P, Andreadis C, et al. P1087: favezelimab (anti–lag-3) and pembrolizumab co-blockade in patients with relapsed or refractory classical hodgkin lymphoma who progressed after anti–pd-1 therapy: an open-label phase 1/2 study. Hemasphere. 2022 Jun 23;6(Suppl):977–8.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!